Literature DB >> 17408468

Genetic polymorphisms associated with priapism in sickle cell disease.

Laine Elliott1, Allison E Ashley-Koch, Laura De Castro, Jude Jonassaint, Jennifer Price, Kenneth I Ataga, Marc C Levesque, J Brice Weinberg, James R Eckman, Eugene P Orringer, Jeffery M Vance, Marilyn J Telen.   

Abstract

Priapism occurs in 30-45% of male patients with sickle cell disease (SCD), but the possible influence of genetic risk factors on the incidence of priapism is not well understood. We examined genetic polymorphisms in 199 unrelated, adult (>18 years), male patients with Hb SS and Hb Sbeta(0)-thalassaemia, 83 (42%) of whom reported a history of priapism. Candidate genes for association with priapism were identified based on their involvement in adhesion, coagulation, inflammation and cell signalling. Additionally, we examined genes involved in nitric oxide biology (NOS2, NOS3, SLC4A1), as well as polymorphisms in the klotho (KL) gene, which has previously been associated with priapism. Strong evidence of association was found for single nucleotide polymorphisms in transforming growth factor-beta receptor, type III (TGFBR3) (rs7526590; P = 0.00058), aquaporin (AQP1) (rs10244884; P = 0.00068), integrin alphav (ITGAV) (rs3768780; P = 0.00090), and the A1 subunit of coagulation factor XIII (F13A1) (hcv1860621; P = 0.00156). Associations with TGFBR3, AQP1, and ITGAV remained significant after adjusting for multiple testing, using the Benjamini-Hochberg procedure. Our data suggest that genes involved in the TGFbeta pathway, coagulation, cell adhesion and cell hydration pathways may be important in risk for priapism.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17408468     DOI: 10.1111/j.1365-2141.2007.06560.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  25 in total

1.  Biomarkers for early detection of sickle nephropathy.

Authors:  Nambirajan Sundaram; Michael Bennett; Jamie Wilhelm; Mi-Ok Kim; George Atweh; Prasad Devarajan; Punam Malik
Journal:  Am J Hematol       Date:  2011-05-31       Impact factor: 10.047

Review 2.  Genetic modifiers of sickle cell disease.

Authors:  Martin H Steinberg; Paola Sebastiani
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

Review 3.  Aquaporins: translating bench research to human disease.

Authors:  A S Verkman
Journal:  J Exp Biol       Date:  2009-06       Impact factor: 3.312

4.  How I treat priapism.

Authors:  Uzoma A Anele; Brian V Le; Linda M S Resar; Arthur L Burnett
Journal:  Blood       Date:  2015-03-25       Impact factor: 22.113

5.  Cutting edge: Role of osteopontin and integrin αv in T cell-mediated anti-inflammatory responses in endotoxemia.

Authors:  Makoto Inoue; Mari L Shinohara
Journal:  J Immunol       Date:  2015-05-13       Impact factor: 5.422

Review 6.  Minireview: Multiomic candidate biomarkers for clinical manifestations of sickle cell severity: Early steps to precision medicine.

Authors:  Steven R Goodman; Betty S Pace; Kirk C Hansen; Angelo D'alessandro; Yang Xia; Ovidiu Daescu; Stephen J Glatt
Journal:  Exp Biol Med (Maywood)       Date:  2016-03-27

Review 7.  Aquaporins in clinical medicine.

Authors:  A S Verkman
Journal:  Annu Rev Med       Date:  2012       Impact factor: 13.739

Review 8.  The search for genetic modifiers of disease severity in the β-hemoglobinopathies.

Authors:  Guillaume Lettre
Journal:  Cold Spring Harb Perspect Med       Date:  2012-10-01       Impact factor: 6.915

9.  Sickle Cell Disease in the Post Genomic Era: A Monogenic Disease with a Polygenic Phenotype.

Authors:  A Driss; K O Asare; J M Hibbert; B E Gee; T V Adamkiewicz; J K Stiles
Journal:  Genomics Insights       Date:  2009-07-30

10.  Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions.

Authors:  Gregory J Kato; Robert P Hebbel; Martin H Steinberg; Mark T Gladwin
Journal:  Am J Hematol       Date:  2009-09       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.